Trial
NCT04031885
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Metastatic Breast Cancer
Intervention
Abemaciclib
Why stopped
Business decision based on the inability to enroll subjects into the trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-24